Trial reportAnnals of family medicine2026
Effect of Self-Sampling HPV DNA Testing on Cervical Cancer Screening in Singapore's Primary Care: Pragmatic Randomized Controlled Trial.
Trial report in Annals of family medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expanding Access to Primary Care Research for Non-English-Speaking Primary Care Providers, Researchers, and Policy Makers.Annals of family medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Singapore, cervical cancer screening rates remain suboptimal, with only clinician sampling included in the national screening program. Self-sampling human papillomavirus (HPV) DNA testing might overcome barriers to clinician-based screening and improve uptake. We assessed the effect of offering self-sampling alongside clinician sampling on screening uptake and high-risk HPV detection compared with clinician sampling alone.
methodsThis pragmatic, 2-arm randomized controlled trial with Zelen design was conducted across NHG Polyclinics, NHG Health in Singapore. Women aged 30-69 years due for cervical cancer screening were randomly assigned (1:1) to intervention (offered selection of clinician sampling followed by self-sampling) or usual care (clinician sampling alone). The primary outcome was high-risk HPV DNA detection, and the secondary outcome was screening uptake. We performed subgroup analysis to examine both outcomes by prior screening history. Multivariable analysis identified factors associated with screening choices.
resultsFrom August 2024 to February 2025, 650 women were randomized, and 640 were included in the analysis (320 per arm). Significantly more high-risk HPV was detected in the intervention arm (3.1% vs 0.3%; absolute difference 2.8%; 95% CI, 0.8-4.8;
conclusionsOffering self-sampling HPV DNA testing alongside clinician sampling significantly increased screening uptake and high-risk HPV detection rates. However, uptake remained lower among women with less education, highlighting the need for targeted engagement strategies.Abstract also available in: عربي (Arabic); Deutsch (German); Español (Spanish); Francais (French); हिन्दी (Hindi); Indonesia (Indonesian); (Chinese); (Japanese); Portugues (Portuguese).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.